Cynapsus Therapeutics Inc. is a specialty central nervous system (CNS) pharmaceutical company. The Company is developing and preparing a sublingual thin filmstrip for the on-demand management of debilitating OFF episodes associated with Parkinson's disease (PD). The Company operates in the research, development and commercialization of a sublingual film for the on-demand management of symptoms associated with PD segment. Its drug candidate, APL-130277, is a sublingual formulation of apomorphine hydrochloride, or apomorphine. The Company's APL-130277 is a turning ON medication designed to convert a PD patient from the OFF to the ON state while avoiding many of the issues associated with subcutaneous delivery of apomorphine. Its APL-130277 is designed to convert all types of OFF episodes, including morning OFF episodes. The Company has initiated its Phase III clinical program for APL-130277. Cynapsus Therapeutics (USA) Inc. is the subsidiary of the Company.